Assessment of Different Niosome Formulations for Optogenetic Applications: Morphological and Electrophysiological Effects

Author:

Celdrán José David1,Humphreys Lawrence12ORCID,González Desirée1,Soto-Sánchez Cristina12ORCID,Martínez-Navarrete Gema12,Maldonado Iván23,Gallego Idoia23ORCID,Villate-Beitia Ilia23ORCID,Sainz-Ramos Myriam23ORCID,Puras Gustavo23ORCID,Pedraz José Luis23ORCID,Fernández Eduardo12ORCID

Affiliation:

1. Biomedical Neuroengineering, Institute of Bioengineering (IB), University Miguel Hernández (UMH), 03020 Elche, Spain

2. Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Carlos III Health Institute (ISCIII), 28029 Madrid, Spain

3. Bioaraba, NanoBioCel Group, School of Pharmacy, University of the Basque Country (UPV/EHU), 01006 Vitoria-Gasteiz, Spain

Abstract

Gene therapy and optogenetics are becoming promising tools for treating several nervous system pathologies. Currently, most of these approaches use viral vectors to transport the genetic material inside the cells, but viruses present some potential risks, such as marked immunogenicity, insertional mutagenesis, and limited insert gene size. In this framework, non-viral nanoparticles, such as niosomes, are emerging as possible alternative tools to deliver genetic material, avoiding the aforementioned problems. To determine their suitability as vectors for optogenetic therapies in this work, we tested three different niosome formulations combined with three optogenetic plasmids in rat cortical neurons in vitro. All niosomes tested successfully expressed optogenetic channels, which were dependent on the ratio of niosome to plasmid, with higher concentrations yielding higher expression rates. However, we found changes in the dendritic morphology and electrophysiological properties of transfected cells, especially when we used higher concentrations of niosomes. Our results highlight the potential use of niosomes for optogenetic applications and suggest that special care must be taken to achieve an optimal balance of niosomes and nucleic acids to achieve the therapeutic effects envisioned by these technologies.

Funder

Spanish “Ministerio de Ciencia, Innovación y Universidades”

European Union’s Horizon 2020 Research and Innovation Programme

Publisher

MDPI AG

Subject

Pharmaceutical Science

Reference52 articles.

1. Gene therapy for human genetic disease?;Friedmann;Science,1972

2. Gene therapy may have future role in cancer treatment;Merz;JAMA,1987

3. Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders;Shahryari;Front. Genet.,2019

4. The approved gene therapy drugs worldwide: From 1998 to 2019;Ma;Biotechnol. Adv.,2020

5. Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy;Powell;Discov. Med.,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3